Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine

Table 4 26-week treatment of exenatide versus insulin glargine, anthropometric-and biochemical parameters

	Exenatide (n = 11)			Insulin glargine (n = 12)			P between groups
	Baseline	Follow-up	P	Baseline	Follow-up	P	Baseline	Follow-up
BMI, kg m⁻²	29.0 ± 2.6	27.6 ± 3.1	<0.01	29.9 ± 3.3	30.0 ± 3.6	0.80	0.47	<0.01
Waist, cm	108 ± 9	104 ± 10.3	<0.01	109 ± 10	110 ± 10	0.53	0.79	<0.01
Biochemical measurements (in fasten state)
HbA1c, %	7.7 ± 1.7	7.1 ± 1.9	<0.01	7.5 ± 0.8	6.8 ± 0.7	<0.01	0.68	0.49
Plasma glucose, mmol L⁻¹	10.4 ± 3.7	9.5 ± 4.0	0.14	9.3 ± 1.6	7.1 ± 1.2	<0.01	0.36	0.03
Total cholesterol, mmol L⁻¹	4.1 ± 1.2	3.8 ± 0.9	0.04	4.3 ± 0.9	4.1 ± 0.9	0.06	0.74	0.25
HDL cholesterol, mmol L⁻¹	0.9 (0.7–1.2)	0.9 (0.8–1.2)	0.92	1.0 (0.9–1.1)	1.0 (1.0–1.1)	0.29	0.54	0.24
LDL cholesterol, mmol L⁻¹	1.9 ± 1.1	1.8 ± 0.9	0.22	2.5 ± 0.7	2.4 ± 0.8	0.17	0.17	0.65
Triglycerides, mmol L⁻¹	1.8 (1.0–3.0)	1.2 (0.9–1.7)	0.04	1.8 (1.1–2.1)	1.4 (0.9–1.6)	0.11	0.87	0.33
Non-esterified fatty acids, mmol L⁻¹	0.6 ± 0.1	0.5 ± 0.2	0.27	0.5 ± 0.1	0.4 ± 0.1	0.09	0.09	0.48
eGRF (MDRD), mL min⁻¹ 1.73 m⁻²	90 ± 35	89 ± 26	0.65	82 ± 22	86 ± 26	0.29	0.52	0.37
Albumin-to-creatinin ratio, g mol⁻¹	0.7 (0.4–1.3)	0.6 (0.4–0.7)	0.88	1.5 (0.7–3.3)	1.2 (0.7–3.5)	0.14	0.09	0.31

Data are mean ± SD, median (interquartile range) or numbers of patients (percentage)
BMI body mass index, HbA1c hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease

ISSN: 1475-2840